Vanguard reports 11.96M shares (8.21%) of ResMed
ResMed Inc beneficial ownership reported by Vanguard Capital Management: 11,961,706.2 shares representing 8.21% of common stock as of 03/31/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ResMed Inc beneficial ownership reported by Vanguard Capital Management: 11,961,706.2 shares representing 8.21% of common stock as of 03/31/2026. The filing states these holdings reflect securities held across Vanguard funds and affiliates, with dispositive power exercised by Vanguard Capital Management LLC.
Insights
Large passive stake disclosed by a major asset manager.
Vanguard Capital Management reports 11,961,706.2 shares ( 8.21%) of ResMed common stock as of 03/31/2026. The filing attributes voting and dispositive arrangements to Vanguard and named affiliates and notes holdings include depository receipts and fund sleeves.
Because the filing is a Schedule 13G, it indicates investment management/ownership reporting rather than an active change in control. Subsequent filings or amendments would show any change in intent or percent ownership.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power regulatory
depository receipts market
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Vanguard Capital Management report in ResMed (RMD)?
Is this Schedule 13G filing an indication Vanguard seeks control of ResMed?
Who else is listed as exercising authority alongside Vanguard?
Are the reported holdings held directly or via funds?
AI-generated analysis. How Rhea-AI works. Not financial advice.